Clinical Trials | September 18, 2025
AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The medicine was well tolerated, with no unexpected safety issue
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
